[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
December 10, 2003

Combined T4 and T3 Therapy—Back to the Drawing Board

Author Affiliations

Author Affiliation: Division of Endocrinology, Sinai Hospital of Baltimore and the Johns Hopkins University School of Medicine, Baltimore, Md. Dr Cooper is Contributing Editor, JAMA.

JAMA. 2003;290(22):3002-3004. doi:10.1001/jama.290.22.3002

Hormone replacement therapy" was originally reported by Murray, who in 1891 described the successful treatment of myxedema with injections of sheep thyroid extract.1 By 1898, therapy for this chronic, severely debilitating condition was hailed as "unparalleled by anything in the whole range of curative measures" by Osler.2 Seven decades later, desiccated thyroid was characterized by the standard thyroid textbook of the day as ". . . as perfect a form of therapy as any known to medicine. . . ."3 With the subsequent identification of thyroxine (T4) and triiodothyronine (T3) as the 2 major thyroid hormones, it was assumed that replacement therapies containing both compounds were more physiological than treatment with either alone. Thus, despite the availability of synthetic T4 in the early 1960s, the prescription of desiccated animal thyroid or synthetic combinations of T4 and T3 continued well into the 1970s.

First Page Preview View Large
First page PDF preview
First page PDF preview
×